Nicotine Products are not a smoking cessation category anymore.The Blurring Boundaries of Nicotine. And that changes everything.
Nicotine pouches show this shift clearly.
They look less like medicine and more like mints.
Consumers prefer formats that don’t make them feel like patients.
In this episode, Filiberto interviews Joel Rubenstein, an LBS alumnus and consumer health veteran, about his consumer health career and the evolution of nicotine products. Rubenstein explains why tobacco companies are moving into cessation/harm reduction: nicotine is both the addictive problem and the cessation ingredient, it is hazardous to manufacture, and cigarette sales are declining. He contrasts highly regulated pharmaceutical players with rapidly innovating non-pharma products (vapes, gums, strips, and especially nicotine pouches), predicting recreational products will outcompete pharma’s. He stresses policymakers often wrongly equate tobacco with nicotine, notes inconsistent regulation (e.g., marijuana legalisation vs pouch bans), and warns unethical marketing, teen targeting, and ultra-strong pouches could trigger backlash, arguing for stronger retailer/supply-chain accountability and self-policing.
00:00 Meet Joel Rubenstein
00:45 From Pfizer to Nicotine
03:11 How Nicotine Evolved
23:37 Pouches vs Pharma Products
35:54 Ethics Regulation and Wrap
What Is Actually Driving Profitable Growth Today?
Our next executive workshops are designed to answer that question directly.
In a confidential, small-group setting, we combine current research, structured frameworks, and open discussion focused on your specific challenges.
Each one-hour session addresses a single strategic issue — Volume vs. Value, Demand Spaces, Shrinking for Growth — with the aim of moving beyond tactics and clarifying where growth is truly coming from, and where it is not.
